Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from conventional immunosuppressants to inebilizumab in AQP4-IgG-positive NMOSD
ChiCTR2400091194Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Percentage of patients with investigator-determined NMOSD relapse within the first year after switching. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2400091194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091194.